+ Watch ICPT
on My Watchlist
Still losing money though less than it did last year. No fewer than 5 directors have made open market sales this month.
undervalued, 4x potential in 3-5 years
Took a breather, now I am ready to be back in.
Market cap over $8 billion?
I picked underperformed because the Intercept Molecule had some negative impact on cholesterol and it seems they didn't fix that problem yet. The FDA will probably want to look deeper into that. Furthermore another company that has a very good molecule is its French competitor: Genfit. It has a molecule that has impressive results so far and a great potential in other fields (so will be able to get multiple revenue stream in the future). The GFT505 (the molecule Genfit is working on) recently got a fast track status from the FDA. I'd be careful of Intercept.
A highly likely buyout target.
Last year I red thumbed Intercept at around 37 based on the too much, too soon concept that the share price had gotten ahead of prospects. That hasn't been a very good strategy for me. I should probably confine myself to red thumbing spikes on BS press releases from companies I know are going to fail eventually. In this case I'm getting behind Intercept not because I buy this whole NASH hysteria, but because OCA is being developed for numerous hepatic indications besides NASH and data will be reported for several of those indications in coming months. Data from the POISE trial in primary biliary sclerosis will be reported next quarter. Encouraging preliminary data from PESTO (portal hypertension) and OBADIAH (bile acid diarrhea) has already been released and more complete data sets will be presented at conferences in April and May respectively.Intercept's share price has receded considerably from the giddy highs in the upper 400's after the FLINT trial was unexpectedly terminated for efficacy at an interim analysis but could certainly revisit those levels and higher if OCA proves as active in other indications as it did for NASH. The zzporte portfolio has 30 shares with a cost basis of 311.
Looks like a joke to me...
Maybe it would continue to go up.
what goes up must come down. lol
IBD EPS, RS, SPROE, Acc ratings plus P/E and div yieldMEDICAL 4 99 DA, NO EARNINGS
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions